Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 170 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Fluticasone furoate Clear all
Completed Phase 3 Interventional Results available

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

NCT01436071
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Long Beach, California • Los Angeles, California • Newport Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01279057
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Results available

BI 671800 ED in Steroid-naive Asthmatic Patients

NCT01092143
View directory record Official record
Conditions
Asthma
Interventions
BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 10, 2026, 6:39 PM EDT
Completed No phase listed Observational

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

NCT02135718
View directory record Official record
Conditions
Asthma
Interventions
ELLIPTA inhaler, Placebo Inhalation Aerosol (MDI)
Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Huntington Beach, California • Newport Beach, California • Vista, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2016 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 4 Interventional Results available

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

NCT00784550
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Bromide, Fluticasone Propionate/Salmeterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 99 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
35
States / cities
Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.

NCT00603746
View directory record Official record
Conditions
Asthma
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
94
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2017 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects

NCT03622112
View directory record Official record
Conditions
Asthma
Interventions
AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 85 Years
Enrollment
808 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
21
States / cities
Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo

NCT01072149
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Furoate (FF)/GW642444 Inhalation Powder, placebo
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
8
States / cities
DeLand, Florida • Orlando, Florida • Madisonville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents

NCT01147848
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone furoate/Vilanterol Inhalation Powder, Fluticasone propionate/salmeterol Inhalation Powder, Placebo (1), Placebo (2)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Huntington Beach, California • Los Angeles, California • Riverside, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Veramyst on the Nasal and Ocular Symptoms of the Early Reaction to Nasal Challenge With Allergen

NCT00791973
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
fluticasone furoate, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 8, 2014 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

Steroids for Pediatric Apnea Research in Kids

NCT02180672
View directory record Official record
Conditions
Obstructive Sleep Apnea Syndrome
Interventions
Nasal Fluticasone, Placebo
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
5 Years to 12 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 1 Interventional

Study of REGN3500 and Dupilumab in Patients With Asthma

NCT03112577
View directory record Official record
Conditions
Asthma, Allergic
Interventions
REGN3500, Dupilumab, Placebo, Fluticasone propionate
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 10, 2026, 6:39 PM EDT
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

NCT01397201
View directory record Official record
Conditions
Asthma
Interventions
Placebo, BI 54903, Fluticasone propionate
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
41
States / cities
Fountain Valley, California • Fullerton, California • Huntington Beach, California + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 3 Interventional Results available

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

NCT01313637
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg, Placebo only
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
1,493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
24
States / cities
Jasper, Alabama • Phoenix, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 10, 2026, 6:39 PM EDT
Withdrawn Phase 2 Interventional

Repeated High-dose Inhaled Corticosteroids for Asthma

NCT00695604
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Fluticasone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Results available

Topical Steroid Treatment for Eosinophilic Esophagitis

NCT00275561
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Fluticasone, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2012 · Synced Oct 10, 2026, 6:39 PM EDT
Active, not recruiting Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619
View directory record Official record
Conditions
Asthma
Interventions
Fp/ABS, FP, ABS, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
12 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
91
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 4 Interventional

Chronic Obstructive Pulmonary Disease Endpoints Study

NCT00358358
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Fluticasone Propionate/Salmeterol 500/50mcg combination, Fluticasone Propionate 500mcg, Salmeterol 50mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Absecon, New Jersey • Charleston, South Carolina • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 4 Interventional Results available

A Clinical Study With Fluticasone Furoate Nasal Spray And Vehicle Placebo For The Treatment Of Perennial (Year-round) Allergic Rhinitis

NCT00682643
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
fluticasone furoate nasal spray, vehicle placebo nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
56
States / cities
Oxford, Alabama • Little Rock, Arkansas • Fresno, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of Multiple Doses of VAK694 in Atopic Subjects With Seasonal Rhinitis

NCT00929968
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Placebo, VAK694, Fluticasone
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Low-Dose ICS Therapy.

NCT00603278
View directory record Official record
Conditions
Asthma
Interventions
GW685698X, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
622 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
95
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 4 Interventional Results available

Study Of Fluticasone Propionate/Salmeterol In Asthmatic Subjects

NCT00517634
View directory record Official record
Conditions
Asthma
Interventions
FP, SFC, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 10, 2026, 6:39 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 10, 2026, 6:39 PM EDT